Details for Patent: 9,216,150

Which drugs does patent 9,216,150 protect, and when does it expire?

Patent 9,216,150 protects VAZALORE and is included in one NDA.

This patent has twenty patent family members in nine countries.

Summary for Patent: 9,216,150

Title:	pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Abstract:	Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.
Inventor(s):	Upendra K. Marathi, Susann Edler Childress, Shaun L. Gammill, Robert W. Strozier
Assignee:	Plx Acquisition Company LLC
Application Number:	US13/908,233
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 9,216,150

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Plx Pharma	VAZALORE	aspirin	CAPSULE;ORAL	203697-001	Jan 14, 2013		OTC	Yes	Yes	9,216,150		Y

International Family Members for US Patent 9,216,150

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012315545
Canada	2850187
China	103957888
European Patent Office	2760433
Hong Kong	1200098
Japan	2014531460